DUBLIN--(BUSINESS WIRE)--Mar. 20, 2013--
Covidien
plc (NYSE: COV) announced the results from today’s Annual General
Meeting. Eight proposals were on the meeting agenda:
-
Election of Directors
-
Appointment of Independent Auditors
-
An advisory vote to approve the Company’s executive compensation
-
Approval of the amended and restated Covidien Stock and Incentive Plan
-
Authorization of the Company and/or any subsidiary to make market
purchases of Company shares
-
Authorization of the reissue price range of treasury shares
-
Amendment of the Company’s Articles of Association to expand the
authority to execute instruments of transfer, and
-
An advisory vote on the creation of distributable reserves for
Mallinckrodt plc.
At the meeting, shareholders elected all 10 nominees, each of whom
currently serves on Covidien’s Board of Directors. They are: José E.
Almeida, Joy A. Amundson, Craig Arnold, Robert H. Brust, John M.
Connors, Jr., Christopher J. Coughlin, Randall J. Hogan, III, Martin D.
Madaus, Dennis H. Reilley and Joseph A. Zaccagnino. In addition, the
Directors elected Mr. Reilley to be the Lead Director, replacing Timothy
M. Donahue, who did not stand for reelection to the Board.
Shareholders also approved the appointment of Deloitte & Touche LLP to
serve as the Company’s independent auditors, and, in an advisory vote,
approved the Company’s executive compensation. Shareholders approved the
amended and restated Covidien Stock and Incentive Plan, authorized
Covidien and/or any of its subsidiaries to make market purchases of
Company shares and authorized the price range at which the Company can
reissue shares it holds as treasury shares. In addition, shareholders
also approved an amendment to Covidien’s Articles of Association to
expand the authority to execute instruments of transfer and, in an
advisory vote, approved the creation of distributable reserves for
Mallinckrodt plc.
About Covidien
Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers
value through clinical leadership and excellence. Covidien manufactures,
distributes and services a diverse range of industry-leading product
lines in three segments: Medical Devices, Pharmaceuticals and Medical
Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000
employees worldwide in 70 countries, and its products are sold in over
140 countries. Please visit www.covidien.com
to learn more about our business.

Source: Covidien plc
Covidien plc Bruce Farmer, 508-452-4372 Vice President Public
Relations bruce.farmer@covidien.com or Coleman
Lannum, CFA, 508-452-4343 Vice President Investor Relations cole.lannum@covidien.com or Todd
Carpenter, 508-452-4363 Senior Director Investor Relations todd.carpenter@covidien.com
|